Change in body mass index and insulin resistance after 1-year treatment with gonadotropin-releasing hormone agonists in girls with central precocious puberty
PurposeGonadotropin-releasing hormone agonist (GnRHa) is used as a therapeutic agent for central precocious puberty (CPP); however, increased obesity may subsequently occur. This study compared body mass index (BMI) and insulin resistance during the first year of GnRHa treatment for CPP.MethodsPatie...
Saved in:
Main Authors: | Jina Park (Author), Jae Hyun Kim (Author) |
---|---|
Format: | Book |
Published: |
Korean Society of Pediatric Endocrinology,
2017-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The influence of gonadotropin-releasing hormone agonists on anthropometric change in girls with central precocious puberty
by: Jong Wan Yoon, et al.
Published: (2017) -
Comparison of the effect of gonadotropin-releasing hormone agonist dosage in girls with central precocious puberty
by: Shinyoung Jang, et al.
Published: (2023) -
Treatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious puberty
by: Hye Ryun Kim, et al.
Published: (2017) -
The influence of gonadotropin releasing hormone agonist treatment on the body weight and body mass index in girls with idiopathic precocious puberty and early puberty
by: Sung Woo Kim, et al.
Published: (2017) -
Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone agonist with or without growth hormone
by: Mo Kyung Jung, et al.
Published: (2014)